pH-sensitive fibronectin nanogels combined with UTMD for anti-atherosclerosis treatment through anti-inflammatory and antioxidant effects
Source abstract
Abstract
The reactive oxygen species (ROS) and inflammatory factors secreted by macrophages play pivotal roles in all stages of atherosclerotic progression. Achieving targeted plaque localization while simultaneously reducing ROS levels to exert both anti-inflammatory and antioxidant effects remains a significant challenge. In this work, we developed a pH sensitive curcumin (Cur)-loaded fibronectin (FN) nanogels, combined with ultrasound-targeted microbubble destruction (UTMD) to enhance therapeutic efficacy via cavitation effects. The FN/FBA-PEG-FBA@Cur (denoted as FNC) nanogels demonstrated a targeted effect on atherosclerosis sites, attributed to the strong affinity between the RGD sequence on FN and the integrins highly expressed on the surface of plaque cells. Moreover, the Schiff base linkages in the nanogels respond to the acidic microenvironment within atherosclerosis plaques, leading to the controlled Cur release, which enable anti-inflammatory and antioxidant activity to attenuate plaque progression. Both in vitro and in vivo experiments confirmed enhanced suppression of plaque progression following treatments with FNC nanogels under UTMD. In summary, the FN nanogels capable of targeting to atherosclerosis plaques offers a promising therapeutic approach for atherosclerosis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Atherosclerosis and Cardiovascular Diseases · Cell Adhesion Molecules Research · Neutrophil, Myeloperoxidase and Oxidative Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Atherosclerosis: recent developments10.1016/j.cell.2022.04.004 ↗
2. CD47- and integrin α4/β1-comodified-macrophage-membrane-coated nanoparticles enable delivery of colchicine to atherosclerotic plaque
3. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society10.1093/eurheartj/ehad472 ↗
4. Cytokines in atherosclerosis: pathogenic and regulatory pathways10.1152/physrev.00024.2005 ↗
5. Inflammation and the development of atherosclerosis10.5551/jat.7591 ↗
6. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis10.1016/j.redox.2018.09.025 ↗
7. Oxidative stress-induced endothelial dysfunction in cardiovascular diseases10.31083/j.fbl2703105 ↗
8. Antioxidants and atherosclerosis: mechanistic aspects10.3390/biom9080301 ↗
9. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis10.1155/2020/5245308 ↗
10. Athero-inflammatory nanotherapeutics: ferulic acid-based poly(anhydride-ester) nanoparticles attenuate foam cell formation by regulating macrophage lipogenesis and reactive oxygen species generation10.1016/j.actbio.2017.05.029 ↗
11. Pro-inflammatory serum amyloid a stimulates renal dysfunction and enhances atherosclerosis in Apo E-deficient mice10.3390/ijms222212582 ↗
12. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention10.1038/s41392-022-00955-7 ↗
13. The combined role of P- and E-selectins in atherosclerosis10.1172/JCI3001 ↗
14. Lipid lowering combination therapy: from prevention to atherosclerosis plaque treatment10.1016/j.phrs.2023.106738 ↗
15. Molecular and biological interactions of fibronectin10.1038/jid.1982.12 ↗
16. Fibroblasts secrete fibronectin under lamellipodia in a microtubule- and myosin II–dependent fashion10.1083/jcb.202204100 ↗
17. Activated T lymphocytes and macrophages secrete fibronectin which strongly supports cell adhesion10.1016/0008-8749(92)90154-H ↗
18. Sinusoidal endothelial cells from Guinea pig liver synthesize and secrete cellular fibronectin in vitro10.1002/hep.1840070511 ↗
19. Upregulation of fibronectin and its integrin receptors - an adaptation to isolation stress that facilitates tumor initiation10.1242/jcs.261483 ↗
20. Cell-matrix interactions, the role of fibronectin and integrins. A survey10.1016/j.patbio.2011.10.003 ↗
21. New perspectives in cell adhesion: RGD and integrins10.1126/science.2821619 ↗
22. Effect of RGD content in poly(ethylene glycol)-crosslinked poly(methyl vinyl ether-alt-maleic acid) hydrogels on the expansion of ovarian cancer stem-like cells10.1016/j.msec.2020.111477 ↗
23. Omentin-1 modulates macrophage function via integrin receptors αvβ3 and αvβ5 and reverses plaque vulnerability in animal models of atherosclerosis10.3389/fcvm.2021.757926 ↗
24. Dendrimer-mediated intracellular delivery of fibronectin guides macrophage polarization to alleviate acute lung injury10.1021/acs.biomac.2c01318 ↗
25. Brain delivery of fibronectin through bioactive phosphorous dendrimers for Parkinson's disease treatment via cooperative modulation of microglia
26. Nanoparticle-mediated multiple modulation of bone microenvironment to tackle osteoarthritis10.1021/acsnano.4c00909 ↗
27. Bioactive phosphorus dendrimers as a universal protein delivery system for enhanced anti-inflammation therapy10.1021/acsnano.3c09589 ↗
28. Cellular and molecular mechanisms of curcumin in prevention and treatment of disease10.1080/10408398.2018.1552244 ↗
29. Preparation, characterization and antioxidant properties of curcumin encapsulated chitosan/lignosulfonate micelles10.1016/j.carbpol.2021.119080 ↗
30. Amphiphilic polymeric nanoparticles encapsulating curcumin: Antioxidant, anti-inflammatory and biocompatibility studies10.1016/j.msec.2020.111793 ↗
31. Improving ultrasound gene transfection efficiency in vitro10.37015/AUDT.2019.190814 ↗
32. Highlights in ultrasound-targeted microbubble destruction-mediated gene/drug delivery strategy for treatment of malignancies10.1016/j.ijpharm.2021.121412 ↗
33. Downregulation of GSK-3β expression via ultrasound-targeted microbubble destruction enhances atherosclerotic plaque stability in New Zealand rabbits10.1016/j.ultrasmedbio.2020.11.002 ↗
34. Platelet membrane biomimetic nanoparticles combined with UTMD to improve the stability of atherosclerotic plaques
35. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases